Announcements Trials
Browse Landscape Eligibility

Clinical Trials

2 trials
RecentStart dateEnrollment
HA 22 × Clear all

Phase

Phase 2 1

Status

Terminated 1Approved for marketing 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Hairy Cell 1Leukemia 1

Interventions

Cyclophosphamide 2681Cisplatin 2665Carboplatin 2462Radiotherapy 2370Paclitaxel 2264Gemcitabine 2128pembrolizumab 1993Docetaxel 1883Bevacizumab 1821Fluorouracil 1548Capecitabine 1532Oxaliplatin 1440Dexamethasone 1330Nivolumab 1300Doxorubicin 1260Rituximab 1249Magnetic Resonance Spectroscopy 1150Etoposide 1126Irinotecan 1038Leucovorin 1020Drug Therapy 999Cytarabine 964Pemetrexed 891fludarabine 889Specimen Handling 822Vincristine 793Lenalidomide 791Cetuximab 785Prednisone 785Trastuzumab 785

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT03501615 2020-06-29

MOXE

AstraZeneca

Approved for marketing
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell

NCT02338050 2015-09-16

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Center for International Blood and Marrow Transplant Research

Phase 2 Terminated
1 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡